While PD-L1 expression in the primary tumor was low (TPS < 1%), this aligns with recent findings that in POLE-mutated colorectal cancers, PD-L1 may not be a reliable biomarker of immunotherapy response. This evidence concerns the gene CD274 and neoplasm.